A review of modifications to recombinant antibodies: Attempt to increase efficacy in oncology applications

Critical Reviews in Oncology/Hematology

Volumn 40, Issue 1, 2001, Pages 25-35

  Reff, Mitchell E ^a   Heard, Cheryl ^a  

^a BIOGEN   (United States)

Author keywords

Antibody drug conjugates; Bispecific antibodies; Monoclonal antibodies; Monoclonal antibody effector function; Monoclonal antibody pharmacokinetics; Single chain Fv

Indexed keywords

ABCIXIMAB; CALICHEAMICIN; CYTOTOXIC AGENT; DIPHTHERIA TOXIN; DOXORUBICIN; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOTOXIN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; PALIVIZUMAB; PRODRUG; RECOMBINANT ANTIBODY; RICIN; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ZENEPAX; ZINOSTATIN;

ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; BINDING AFFINITY; CHEMICAL ENGINEERING; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; ENGINEERING; EXPERIENCE; HUMAN; INFORMATION; ISOTOPE LABELING; NONHUMAN; ONCOLOGY; REVIEW; SOLID TUMOR; TARGET CELL;

EID: 0034803102     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00132-9     Document Type: Review

References (86)

1. Continuous cultures of fused cells secreting antibody of predefined specificity
2. Suppression of human anti-mouse antibody response to murine monoclonal antibody L6 by deoxyspergualin: A phase I study
3. Human/mouse chimeric antibodies show low reactivity with human anti-murine antibodies (HAMA)
4. Human immune response to monoclonal antibodies
5. The OKT3 antibody response study: A multicenter study of human anti-mouse antibody (HAMA) production following OKT3 use in solid organ transplantation
6. Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains
7. Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma
8. Pharmacokinetics, immune response and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody
9. Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (Human g4) monoclonal antibody in humans
10. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses
11. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety, and pharmacokinetics
12. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
13. Replacing the complementarity-determining regions in a human antibody with those from a mouse
14. Possible use of similar framework region amino acid sequences between human and mouse immunoglobulins for humanizing mouse antibodies
15. Development of a humanized monoclonal antibody (MEDI-95) with potent in vitro and in vivo activity against respiratory syncytial virus
16. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival
17. Humanization of an anti-p185HER2 antibody for human cancer therapy
18. Primitization' of recombinant antibodies for immunotherapy of human diseases: A macaque/human chimeric antibody against human CD4
19. In vitro IgE inhibition in B cells by anti-CD23 monoclonal antibodies is functionally dependent on the immunoglobulin Fc domain
20. By-passing immunization human antibodies from V-gene libraries displayed on phage
21. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
22. Human antibodies from transgenic mice
23. Production of fully human antibodies by transgenic mice
24. Human monoclonal antibodies isolated from spontaneous Epstein-Barr virus-transformed tumors of Hu-SPL-SCID mice and specific for fusion protein display broad neutralizing activity toward respiratory syncytial virus
25. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation
26. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
27. Mouse/human chimeric monoclonal antibody in man: Kinetics and immune response
28. Monoclonal antibody-directed cytotoxic therapy
29. Targeting strategies for cancer radiotherapy
30. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: A phase I trial of daily bolus infusion
31. Single-chain immunotoxins directed at the human transferin receptor containing Pseudomonas exotoxin A or diphtheria toxin: Anti-TRF(Fv)-PE40 and DT388-anti-TFR(Fv)
32. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of a monoclonal antibody specific for the carcinoembryonic antigen
33. A summary of monoclonal antibody-enzyme/prodrug
34. Formation of bispecific antibody by the use of leucine zippers
35. Expression and characterization of a chimeric bifunctional antibody with therapeutic applications
36. Bispecific antibodies in cancer therapy, from the laboratory to the clinic
37. Human antibody effector function
38. Production of characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide
39. Studies of aglycosylated chimeric mouse-human IgG: Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region
40. Finally! The Brambell Receptor (FcRB): Mediator of transmission of immunity and protection from catabolism for IgG
41. FcRn: The MHC class I-related receptor that is more than an IgG transporter
42. The protection receptor for IgG catabolism is the b2-microglobulin-containing neonatal intestinal transport receptor
43. Improving antibody affinity by mimicking somatic hypermutation in vitro
44. 3-specific humanized mAb
45. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: Use of phage display to improve affinity and broaden strain reactivity
46. By-passing immunization building high affinity human antibodies by chain shuffling
47. 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: Effects of dose and EDTA coadministration on pharmacokinetics and toxicity
48. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to resporatory syncytial virus in premature infants and infants with bronchopulmonary dysplasia
49. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytical virus in premature infants and infants with bronchopulmonary dysplasia
50. Clinical trials and therapeutics, efficacy, pharmacodynamics, and pharmacokinetics of CGP 51901, an anti-immunoglobulin e chimeric monoclonal antibody, in patients with seasonal allergic rhinitis
51. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RSHZ19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers
52. Pharmacokinetics of human-mouse chimeric anti-GD2 mAb ch14.18 in a phase I trial in neuroblastoma patients
53. CDP571, a humanized antibody to human tumor necrosis factor-a: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock
54. Targeting of tumors with murine and reshaped human monoclonal antibodies against placental alkaline phosphatase: Immunolocalisation, pharmacokinetics and immune response
55. Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. First Communication: Lasma concentration, distribution, metabolism and excretion of the new monoclonal antibody, regavirumab after intravenous administration in rats and rabbits
56. Comparative binding and preclinical localization and therapy studies with radiolabeled human chimeric and murine 17-1A monoclonal antibodies
57. Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients
58. Biological properties of a CD4 immunoadhesin
59. 99mTc: The role of metabolism and kinetics
60. Abciximab: An updated review of its use in ischaemic heart disease
61. Superantigen-based immunotherapy: A phase I trial of PNU-214565, a monoclonal antibody-staphylococcal enterotoxin a recombinant fusion protein, in advanced pancreatic and colorectal cancer
62. Pharmacology and biological efficacy of recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass
63. Taking engineered anti-CEA antibodies to the clinic
64. Targeting cancer micrometastases with monoclonal antibodies: A binding-site barrier
65. Therapeutic antobody fragments with prolonged in vivo half-lives
66. Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
67. Monoclonal antibody SN10 which shows a highly selective reactivity with human B leukemia-lymphoma and is effectively internalized into cells
68. + tumour cells in vitro and in SCID mice
69. BR96 sFv-PE40 immunotoxin: Nonclinical safety assessment
70. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin
71. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to enodthelial cells and initiating vascular leak syndrome
72. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates
73. Production, binding and cytotoxicity of human/mouse chimeric monoclonal antibody-neocarzinostatin conjugate
74. Antibody-directed enzyme prodrug therapy: Pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial
75. 2 antibody fragment/cytosine deaminase (pCD2) fusion protein for the antibody directed enzyme prodrug therapy (ADEPT) of solid tumors
76. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human β-glucuronidase for antibody-directed enzyme prodrug therapy
77. Development of a humanized disulfide-stabilized anti-p185HER2 Fv-b-lactamase fusion protein for activation of a cephalosporin doxorubicin prodrug
78. Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules
79. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
80. Anti-CD20 antibody IDEC-C2B8 mediated apoptosis can be blocked by inhibition of caspase 3
81. Cdc2 kinase
82. Signaling antibodies in cancer therapy